Prelude Q1 2025 net loss $32.1M; cash $103.1M funds ops into Q2 2026

Prelude Therapeutics Inc

2025-Q1 EPS reported -$0.42

Cash, cash equivalents, restricted cash and marketable securities of $103.1M as of March 31, 2025.
Net loss of $32.1M ($0.42 per share) vs. $31.4M ($0.42) in Q1 2024; R&D expense $28.8M (+5% YoY).
PRT3789 monotherapy and docetaxel combo dose escalation complete; Phase 2 data expected H2 2025.
PRT7732 Phase 1 advancing in 5th cohort at 60 mg once daily; initial data anticipated H2 2025.
KAT6A degrader program targeting candidate nomination in Q2 2025 and IND in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.